This is a single arm study. The tumor specimen is analyzed for the presence of a fusion protein which corresponds to available peptides. Fresh APCs are utilized for initial priming vaccination. All subsequent vaccinations will use cryopreserved APCs.
Patients undergo cytoreductive therapy for the treatment of their particular malignancy.
This therapy usually consists of multiagent chemotherapy in the context of a separate protocol. Influenza vaccine is administered by intramuscular injection concurrent to peptide-pulsed APC vaccines. Patients with Stage IV or metastatic disease at the time of initial presentation with tumor, prior to any cytoreductive therapy. Patients who have received cytoreductive therapy for Stage IV or metastatic disease may be enrolled at the time of completion of cytoreductive therapy if an apheresis specimen is available. Patients must be less than or equal to 35 years at the time of initial diagnosis of alveolar rhabdomyosarcoma or ESFT, weight greater than 10 kg at the time of apheresis.